


JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA



CATHY BETTS
DIRECTOR
KA LUNA HO'OKELE

JOSEPH CAMPOS II
DEPUTY DIRECTOR
KA HOPE LUNA HO'OKELE

STATE OF HAWAII
KA MOKU'ĀINA O HAWAI'I
DEPARTMENT OF HUMAN SERVICES
KA 'OIHANA MĀLAMA LAWELAWE KANAKA
Med-QUEST Division
Clinical Standards Office
P. O. Box 700190
Kapolei, Hawaii 96709-0190

MINUTES OF REMOTE MEETING
Med-QUEST Drug Use Review (DUR) Board

Date: May 17, 2023

Time: 12:05 pm

Remote Meeting Location: Zoom Meeting participation for members and the public:

<https://medquest-hawaii-gov.zoom.us/j/83012882996?pwd=cEE0TldPUmE5YXhVUE4zMzdrTWp1dz09>

In-Person Location:
Kakuhihewa Building
Conference Rooms 577A and 577B
601 Kamokila Blvd., Kapolei, Hawaii 96707

Members Present:

Wendell Au, past Vice-Chair, Pharmacist
Miki Lei Morita, Pharmacist
Dr. Greg Yuen
Eddie Fox, Medical Service Representative
Kathleen T. Kang-Kaulupali, Clinical Standards Office DUR Coordinator, Pharmacist

Members Absent:

Dr. James Lumeng
Reed Muraoka, Pharmacist

Staff Present:

Marcy Healy, Acting Clinical Standards Office Administrator
Julie Jay, Clinical Standards Office Secretary
Carmel Muenster, Clinical Standards Office Clerk
Michael Mau, Information Technology Specialist

Guest:

Gary Peton, Conduent Government Healthcare (Medicaid fiscal agent)

Public Attendance:

In-person location: None

Virtual: Lisa Ashton

- I. Vice-Chair Wendel Au called the meeting to order at 12:05 p.m., and welcomed participants to the meeting.
- II. Vice-Chair Wendel Au proceeded with a roll call of Board members. A quorum of 5 members was present, as reported by the DUR Coordinator. The Board members were asked to declare if they were not alone. All participating board members declared that they were alone. Other support members of the Drug Use Review Board were noted: Dr. Lynette Honbo, Koan Risk Solutions (not present); Gary Peton, Conduent Government Healthcare (present); Dr. Gavin Uchida, Clinical Standards Office dentist (not present).
- III. Review of meeting participation guidelines and process in regard to the sunshine law, public access to the meeting, providing written and oral testimony, and requiring videos be on for public access as to who is speaking, were shared.
- IV. Review and approval of Minutes of November 10, 2021 was postponed to the August 2023 DUR Board meeting.
- V. Election of Officers: Vice-Chair Wendel Au moved to postpone the election of officers until the August 2023 DUR Board meeting, seconded by Eddie Fox and unanimously approved with no abstentions.
- VI. Dental Program – Data presented by Gary Peton and Kathleen T. Kang-Kaulupali
 - a. First quarter 2022 versus first quarter 2023
 - i. Claims increased with program expansion for adult coverage (see provider memorandum FFS 23-05). In 2022, only children and adult emergency care were covered. The majority are generic drugs dispensed from the dental formulary. Similar antibiotic, pain and anti-inflammatory medications remain in the top 10 claim categories in both years. The formulary continues to meet patient and provider needs.

- ii. Treatments with controlled drugs are monitored for misuse and trends will be reported to the Drug Use Review Board, especially with the increasing adult population. Currently, the controlled drug claim count has increased less than the total drug claim count. Quantity limits have been updated to reflect previous Board recommendations.
 - b. Program expansion on January 1, 2023, for adult dental coverage
 - i. The claim count of total drugs in the second quarter 2023 is increasing and expected to continue and stabilize in third quarter 2023. Four prior authorization requests were received since January 1, 2023, of which two were approved and two were denied. The denied requests were for non-dental medical needs. The formulary continues to meet patient and provider needs.
 - ii. Coverage of fluoride toothpaste was added to the dental formulary, effective January 1, 2023. Per the new Medicaid dental consultant, Dr. Gavin Uchida, fluoride use was analyzed. There were 34 claims in first quarter 2022 and 181 claims in the first quarter 2023. The dental underutilization may be due to fluoride prescribed by medical providers. More fluoride combined with various multiple vitamins are available under medical health plans coverage.
 - c. Public testimony: The Board asked for public testimony and none was received.
- VII. State of Hawaii Organ and Tissue Transplant (SHOTT) Program - Data presented by Gary Peton and Kathleen T. Kang-Kaulupali
 - a. Expensive drug claims greater than \$1,000
 - i. First quarter 2023 review

For 53 drug claims, the cost was \$368,600 for a population size of 30-40. The majority are brand drugs. In contrast, the dental claims are generic and the dental program covers all Medicaid members. Koan prospectively reviews SHOTT patients' medications especially claims over \$25,000 with MQD for program management. Cost reimbursements pay at the lowest of Wholesale Acquisition Cost, National Average Drug Acquisition Cost, Usual and Customary, State Maximum Allowed Cost or Federal Upper Limit.

- b. Public testimony: The Board asked for public testimony and none was received.

- VIII. Next Meeting: The next meeting is scheduled for Wednesday, August 9, 2023.

- IX. Adjourn at 12:44pm: Moved by Eddie Fox, seconded by Dr. Yuen, unanimously approved with no abstentions.